Abstract
Background: Glycemic control and management of dyslipidemia to reduce cardiovascular risk are major therapeutic goals in individuals with type 2 diabetes mellitus (T2DM). This study was performed to evaluate the effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ (PPARα/γ) agonist, on both lipid and glycemic parameters in obese, hypertriglyceridemic, insulin-resistant rhesus monkeys.
Keywords: Aleglitazar, Glycemic, Primate model
Fig.1.Study design. PK, pharmacokinetics.
Tel : 028-8592-1823 (in China)
Tel:+1-517-388-6508 (in US)
Tel : +86 (28) 8592-1823 (outside of China)
Fax : +86-28-62491302
Zip code : 610041
Address: No.88, Keyuan South Road, Hi-tech Zone, Chengdu, Sichuan Province, China